ライフサイエンスコーパス: transgenic mouse model

1 with cognitive improvements in an AD APP/PS1 transgenic mouse model.

2 impaired decidualization in both women and a transgenic mouse model.

3 progression of retinal pathology in a PD/DLB transgenic mouse model.

4 was further demonstrated in vivo using a CLL transgenic mouse model.

5 different EAE models, including the 2D2 TCR-transgenic mouse model.

6 and elicit functional improvement in an aged transgenic mouse model.

7 ing breast cancer progression in a MMTV-PyMT transgenic mouse model.

8 etworks and inhibited tumor progression in a transgenic mouse model.

9 U2AF1 mutation using a doxycycline-inducible transgenic mouse model.

10 intracerebroventricular infusion in an aged transgenic mouse model.

11 eractions to induce leukemia in the Emu-TCL1 transgenic mouse model.

12 I and circulates as free plasma species in a transgenic mouse model.

13 and prevents mammary cancer development in a transgenic mouse model.

14 vel cardiac-specific TetON-miR-133 inducible transgenic mouse model.

15 hesis that PAD2 promotes oncogenesis using a transgenic mouse model.

16 profiles and behavioral changes in a G72/G30 transgenic mouse model.

17 utant HTT expression in vivo in the N171-82Q transgenic mouse model.

18 autoimmune cascade of PV in a humanized HLA-transgenic mouse model.

19 tient samples and the RIP1-Tag2 (RT2) PanNET-transgenic mouse model.

20 constructed an adipose tissue-specific G0S2 transgenic mouse model.

21 metabotropic glutamate receptor 1 (Grm1(Tg)) transgenic mouse model.

22 ed Jagged1 using osteoblast-specific Jagged1 transgenic mouse model.

23 stemic anaphylaxis in human FcepsilonRIalpha transgenic mouse model.

24 ase (SCD) in a NRF2 knockout (SCD/NRF2(-/-)) transgenic mouse model.

25 apoptosis mediated by the p53 pathway in our transgenic mouse model.

26 cells, using a unique T cell receptor (TCR) transgenic mouse model.

27 ed this hypothesis, using highly replicative transgenic mouse models.

28 using tetracycline- and tamoxifen-inducible transgenic mouse models.

29 of Interleukin (IL)-10 in the brains of APP transgenic mouse models.

30 ain and in Abeta precursor protein (AbetaPP) transgenic mouse models.

31 een greatly accelerated by the generation of transgenic mouse models.

32 rming activity of sTAg in vivo in a panel of transgenic mouse models.

33 set of focal and vascular amyloid in AD-like transgenic mouse models.

34 osition was analyzed in 12 different AD-like transgenic mouse models.

35 tau protein aggregation both in vitro and in transgenic mouse models.

36 In the mThy1-human alpha-synuclein transgenic mouse model, a decrease in alpha-synuclein ac

37 We showed that in a transgenic mouse model, activation of the UPR in early d

38 diomyocyte-specific, doxycycline-regulatable transgenic mouse model aggravated cardiac hypertrophy, f

39 riggers, could prevent disease symptoms in a transgenic mouse model and a knockin mouse model of the

40 urther generated a corresponding betaH1-eGFP transgenic mouse model and demonstrated the presence of

41 t manner, and is strongly activated in 5XFAD transgenic mouse model and human AD brains.

42 interstitial fluid (ISF) and CSF from an AD transgenic mouse model and postmortem ventricular and an

43 We generated a cardiomyocyte-targeted Nox2-transgenic mouse model and studied the effects of in viv

44 Using various inducible and site-specific transgenic mouse models and pharmacological validation e

45 mmary gland tumors in a ErbB2-overexpressing transgenic mouse model, and in-vitro evidence that PKCde

46 tissue; CC cell xenografts; a p53-deficient transgenic mouse model; and a non-transgenic, chemically

47 heir functions in prostate, we established a transgenic mouse model (AR3Tg) with targeted expression

48 s decreased in the brains of AD patients and transgenic mouse model, as well as Abeta-treated cells.

49 This work describes the first double transgenic mouse model bearing both human FcRn and HSA g

50 We found that in a double transgenic mouse model carrying activated Wnt1 and mutan

51 Using transgenic mouse models, cell line-based functional stud

52 In the translational realm, transgenic mouse models continue to be used, with a rece

53 st time Pcdh10 up-regulation in tissues from transgenic mouse models, cultured Schwann cells, and hum

54 tution of bone marrow cells into a TGF-alpha transgenic mouse model demonstrated that fibrocytes do n

55 In a somatic transgenic mouse model, depletion of Bcl6 inhibits the p

56 This transgenic mouse model-derived gene signature provides a

57 ire breadth to a non-self-antigen, a TCRbeta transgenic mouse model (EF4.1) expressing a limited, yet

58 Furthermore, transgenic mouse models enabled us to identify which of

59 Using a transgenic mouse model engineered so that lactogenic hor

60 first report of a newly generated humanized transgenic mouse model engineered to express human NRG1-

61 Here, we present a novel transgenic mouse model expressing a hepatocyte-specific

62 Here we use a controllable transgenic mouse model expressing a mutant form of amylo

63 In this study, we present a transgenic mouse model expressing a photoactivated adeny

64 In a transgenic mouse model expressing a VEGF-C/D trap and di

65 This transgenic mouse model expressing an ERalpha folding-bio

66 Boosting a transgenic mouse model expressing germline VRC01 heavy c

67 c alleviated S. pyogenes-induced sepsis in a transgenic mouse model expressing human FH (S. pyogenes

68 Here we show in a transgenic mouse model expressing mutant human tau predo

69 er mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOG

70 We generated a transgenic mouse model expressing the E7 oncoprotein of

71 A tetracycline-inducible transgenic mouse model expressing truncated beta-catenin

72 Transgenic mouse models expressing mutant superoxide dis

73 impact of TDP-43 dysfunction, we generated a transgenic mouse model for a partial loss of TDP-43 func

74 he advantages and limitations of the HLA-DR4 transgenic mouse model for evaluating human C. trachomat

75 id leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia.

76 Using transgenic mouse models for cell-specific HIF expression

77 Using autochthonous transgenic mouse models for inducible FGFR1 (JOCK1) and

78 Using recently developed transgenic mouse models for LIN28B and let-7g, we demons

79 t composition in the skin, we have generated transgenic mouse models for tamoxifen-inducible de novo

80 ) and previously undescribed (G2-Gata4(Cre)) transgenic mouse models for the study of coronary vascul

81 ue expression in Tg32, a human FcRn knock-in transgenic mouse model, for which a strong correlation o

82 Using the TRAMP transgenic mouse model, glipizide, a widely used drug fo

83 rmacodynamic and pharmacokinetic assays in a transgenic mouse model harboring the human receptors, no

84 of IR-induced DSBs to GBM development using transgenic mouse models harboring brain-targeted deletio

85 exanucleotide repeat expansion in ALS/FTD, a transgenic mouse model has remained elusive.

86 Several transgenic mouse models have been developed which facili

87 Over the past few decades, transgenic mouse models have been increasingly used to s

88 n the majority of Rett Syndrome (RTT) cases, transgenic mouse models have played a critical role in o

89 Biophysical and transgenic mouse models have provided insight into the m

90 ine phosphatases Shp1 and Shp2, knockout and transgenic mouse models have revealed distinct phenotype

91 Transgenic mouse models helped to identify key regulator

92 in prostatic tissues of TRAMP (autochthonous transgenic mouse model), human CaP patients, and in cell

93 Using a transgenic mouse model in which FlnA is selectively depl

94 severative behaviors, we characterized a new transgenic mouse model in which inducible ablation of SC

95 cted CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted

96 We used a novel transgenic mouse model in which the human diphtheria tox

97 V-induced skin carcinogenesis, we utilized a transgenic mouse model in which the keratin 14 promoter

98 Here, we use an inducible transgenic mouse model in which the pro-apoptotic gene B

99 We have developed a new transgenic mouse model in which we can induce expression

100 Here, we describe a transgenic mouse model in which we expressed a mitochond

101 We studied autoresuscitation in two transgenic mouse models in which exocytic neurotransmitt

102 injury pharmacologically and genetically in transgenic mouse models in which microglia and systemic

103 Here, we studied 2 transgenic mouse models in which nonmuscle myosin heavy

104 morigenesis, we developed an inducible Nanog transgenic mouse model, in which the expression of Nanog

105 receptors has been characterized in anti-DNA transgenic mouse models including 3H9, 3H9/56R, and thei

106 Studies in a transgenic mouse model indicated that these compounds co

107 ation and improves survival in a calcineurin transgenic mouse model, indicating that COUP-TFII may se

108 Using a transgenic mouse model inducibly expressing a dominant-n

109 This hAS transgenic mouse model is therefore an ideal animal mode

110 fic dominant-negative (DN) TCF7L2 (TCF7L2DN) transgenic mouse model LTCFDN.

111 ow for the first time that, unlike other tau transgenic mouse models, minimal expression of a human d

112 We developed a transgenic mouse model, Mito-Ob, overexpressing prohibit

113 Here, we developed a transgenic mouse model (NRG1-IV/NSE-tTA) in which human

114 uppress the Alzheimer's-like phenotypes in a transgenic mouse model of Abeta deposition.

115 to investigate brain copper trafficking in a transgenic mouse model of AD by PET imaging with (64)Cu,

116 that reducing endogenous alpha-syn in an APP transgenic mouse model of AD prevented the degeneration

117 In a transgenic mouse model of AD, aducanumab is shown to ent

118 In an APP transgenic mouse model of AD-like amyloid pathology we f

119 which demonstrated oral activity in a triple-transgenic mouse model of AD.

120 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model of AD.

121 we confirm these results in vivo by using a transgenic mouse model of AD.

122 ould exert beneficial effects in the Tg19959 transgenic mouse model of AD; Tg19959 mice express the h

123 pening of the blood-brain barrier (BBB) in a transgenic mouse model of advanced Alzheimer disease (AD

124 In a G85R SOD1YFP transgenic mouse model of ALS, which becomes paralyzed b

125 rovements in synaptic plasticity on a triple transgenic mouse model of Alzheimer's disease (3xTg-AD)

126 genous alpha-synuclein (alpha-syn) in an APP transgenic mouse model of Alzheimer's disease (AD) preve

127 S)-induced microglia activation in vivo in a transgenic mouse model of Alzheimer's disease (APP/PS1)

128 subsequent fluorescent amyloid staining in a transgenic mouse model of Alzheimer's disease (tgSwe).

129 binant CSF1 ameliorates memory deficits in a transgenic mouse model of Alzheimer's disease.

130 el of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer's disease.

131 d in affected neuronal tissues from a TDP-43 transgenic mouse model of amyotrophic lateral sclerosis

132 In a transgenic mouse model of androgen-responsive prostate c

133 are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by

134 D8+ T cells are implicated as effectors in a transgenic mouse model of autoimmune GFAP meningoencepha

135 elerated lymphoma development in the Emu-Myc transgenic mouse model of B lymphoma and that silencing

136 In an S100A7 transgenic mouse model of breast cancer (mS100a7a15 mice

137 of CaSR-PTHrP interactions in the MMTV-PymT transgenic mouse model of breast cancer and in human bre

138 In the MMTV-PyMT transgenic mouse model of breast cancer and in oral squa

139 n is sufficient to induce tumorigenesis in a transgenic mouse model of breast cancer.

140 results in suppression of tumour growth in a transgenic mouse model of breast cancer.

141 W)-MRI in the polyoma virus middle T antigen transgenic mouse model of breast cancer.

142 In a transgenic mouse model of cancer, the B7-H3-targeted ult

143 igated the impact of gammadelta T cells in a transgenic mouse model of carcinogenesis induced by HPV1

144 METHODS AND Using a transgenic mouse model of cardiac lipotoxicity overexpre

145 in C57BL/6 mice, guinea pigs, and in an APP transgenic mouse model of cerebral amyloidosis (Tg2576).

146 on of HBV-specific CD8 T cell responses in a transgenic mouse model of chronic HBV infection.

147 We used a transgenic mouse model of chronic lung disease induced b

148 used patient samples and the Emu-TCL1 (TCL1) transgenic mouse model of CLL, which results in spontane

149 vivo relevance of this pathway in our IL-15 transgenic mouse model of CTCL by showing that interfere

150 In this study we have used a transgenic mouse model of dementia (rTg4510 mice) which

151 In this study we have used a transgenic mouse model of dementia (rTg4510 mice), which

152 logical approaches, we have shown that, in a transgenic mouse model of dementia, the functional prope

153 Here, we used a transgenic mouse model of diabetes to probe the gene exp

154 GMP signaling.SIGNIFICANCE STATEMENT In DYT1 transgenic mouse model of dystonia, PDE10A, a key enzyme

155 In the PS19 transgenic mouse model of FTD, administration of salsala

156 ured cells and into neuronal inclusions in a transgenic mouse model of FUSopathy.

157 nt stem cells into the anterior chamber of a transgenic mouse model of glaucoma.

158 We created a transgenic mouse model of HCDD using targeted insertion

159 Using a conditional transgenic mouse model of HD, in which the mice express

160 ivity and local field potentials in the R6/2 transgenic mouse model of HD.

161 and improves phenotype and survival in R6/2 transgenic mouse model of HD.

162 ilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle

163 In the K14-HPV16 transgenic mouse model of HPV-driven neoplasms, direct c

164 Using an established transgenic mouse model of HPV16 E7-induced HNSCC, we dem

165 rogression of carcinogenesis in the K14E6/E7 transgenic mouse model of human papillomavirus-associate

166 Here we report novel findings in the R6/2 transgenic mouse model of Huntington's disease (HD) by d

167 p and electroencephalogram disturbances in a transgenic mouse model of Huntington's disease (R6/2 mic

168 duced in striatal output neurons of the R6/2 transgenic mouse model of Huntington's disease, at an ag

169 dependent microvascular disease is seen in a transgenic mouse model of IFN toxicity.

170 Using a human islet amyloid polypeptide transgenic mouse model of islet amyloidosis, we show ARC

171 In this study, we describe a transgenic mouse model of KRAS-driven lung adenocarcinom

172 In a syngeneic HLA-A2-transgenic mouse model of large established tumors, we f

173 y used on tumor tissue extracts from a K-ras transgenic mouse model of lung cancer to enhance our und

174 xoguanine DNA glycosylase (OGG1) in the PyMT transgenic mouse model of mammary tumorigenesis.

175 ymal transition and metastasis, an MMTV-PyMT transgenic mouse model of mammary tumour progression and

176 Here, we further characterized a lethal transgenic mouse model of MERS-CoV infection and disease

177 ganglion cell layer of MS patients and in a transgenic mouse model of MS (ND4 mice).

178 teolipid protein alpha-syn (PLP-SYN) mice, a transgenic mouse model of MSA.

179 patients and reduced IGF-1 brain levels in a transgenic mouse model of multiple system atrophy.

180 Using a "humanized" transgenic mouse model of nasal colonization, we took a

181 (iii) Immunization of an HLA-A*02:01 transgenic mouse model of ocular herpes with "ASYMP" CD8

182 Using a transgenic mouse model of Parkinson's disease (PD) that

183 our results show in an aggressively growing transgenic mouse model of PDAC that the coordinated acti

184 We previously generated a transgenic mouse model of PPFP thyroid carcinoma and sho

185 n early pathological stage, in the THY-Tau22 transgenic mouse model of progressive AD-like tau pathol

186 se hypotheses were tested using cells from a transgenic mouse model of prostate cancer infected with

187 We investigated this issue in a transgenic mouse model of prostate cancer treated by tra

188 nic adenocarcinoma of mouse prostate (TRAMP) transgenic mouse model of prostate cancer.

189 We used a transgenic mouse model of pulmonary arterial hypertensio

190 In a transgenic mouse model of resectable PDAC, we investigat

191 We validated this method in a transgenic mouse model of selective podocyte depletion,

192 mtDNA genomes on the background of the PyMT transgenic mouse model of spontaneous mammary carcinoma.

193 emporal structure of SWRs was disrupted in a transgenic mouse model of tauopathy (one of the major ha

194 s, neuroinflammation, neurodegeneration in a transgenic mouse model of tauopathy.

195 ct of HCU on hepatic cysteine oxidation in a transgenic mouse model of the disease.

196 Here we introduce the first transgenic mouse model of uveal melanoma, which develops

197 To test this, we used a previously described transgenic mouse model of wound-induced skin tumorigenes

198 Lesions of the LC in amyloid-based transgenic mouse models of AD exacerbate Abeta pathology

199 ortem brain tissue samples from AD patients, transgenic mouse models of AD, and neuronal cells were u

200 atients with Alzheimer's disease (AD) and in transgenic mouse models of AD.

201 opathology and cognitive deficits in several transgenic mouse models of AD.

202 low-up of beta-amyloid (Abeta) deposition in transgenic mouse models of Alzheimer disease (AD) would

203 was activated in reactive astrocytes in two transgenic mouse models of Alzheimer's disease and in a

204 hese results were confirmed in vivo by using transgenic mouse models of Alzheimer's disease in which

205 ulates amyloidosis and memory impairments in transgenic mouse models of Alzheimer's disease.

206 s amyloid aggregation in cells, worms and in transgenic mouse models of Alzheimer's disease.

207 29 would attenuate pulmonary hypertension in transgenic mouse models of Bmpr2 mutation.

208 derived tumor xenograft (PDX) and MYC-driven transgenic mouse models of breast cancer by inhibiting t

209 icated faithfully in MMTV-PyMT and MMTV-Her2 transgenic mouse models of breast cancer.

210 a result of tumor formation in two different transgenic mouse models of cancer (RIP1-Tag2 model of in

211 Using transgenic mouse models of cancer, we found that express

212 oglia are associated with amyloid plaques in transgenic mouse models of cerebral amyloidosis and in h

213 slocation, MCL has not been recapitulated in transgenic mouse models of cyclin D1 overexpression alon

214 Here we show that in transgenic mouse models of early AD, direct optogenetic

215 olysis events observed in vivo, we generated transgenic mouse models of HD representing five distinct

216 Here, we use bacterial artificial chromosome transgenic mouse models of LRRK2 to explore potential no

217 f Nrf2/ARE genes is neuroprotective in other transgenic mouse models of neurodegenerative diseases an

218 breast cancer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer.

219 emonstrate a significant analgesic effect in transgenic mouse models of SCD and cancer as well as com

220 ion of SMN protein in human cells and in two transgenic mouse models of SMA.

221 Disappointingly, the initial enthusiasm for transgenic mouse models of the disease has not been foll

222 s mutant SOD1 expression is recapitulated in transgenic mouse models of the disease.

223 To address this gap, we developed two transgenic mouse models on the C57BL/6 background by ove

224 G30 genomic region was used to establish the transgenic mouse model, on which gene expression studies

225 in DIV7 cortical cultures of either from E18 transgenic mouse model or from rat E18 embryos that were

226 We therefore generated a double-transgenic mouse model overexpressing both human heparan

227 In transgenic mouse models, overexpression of Sox2 leads to

228 Here, we use transgenic mouse models producing CAA mutants (Tg-SwDI)

229 Aha1 overexpression in the rTg4510 tau transgenic mouse model promoted insoluble and oligomeric

230 in LTP/LTD magnitude seen across ages in AD transgenic mouse models reflect the inability to undergo

231 nfection model and a lethal model makes this transgenic mouse model relevant for advancing MERS resea

232 IL-1alpha in prostatic epithelial cells in a transgenic mouse model resulted in increased prostate si

233 turely terminated MHC-TCR/CD4 interaction in transgenic mouse models results in lineage redirection,

234 ified a beneficial taxonomic repertoire in a transgenic mouse model (RIP140mvarphiKD) which resists t

235 Here we report that, in a transgenic mouse model simulating the duplication condit

236 In a hAPP transgenic mouse model, substantial levels of GM1-bound

237 Evidence from transgenic mouse models suggests mutant forms of FUS exe

238 riven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Mal

239 e therapeutic profile of CpG ODN in a triple transgenic mouse model, Tg-SwDI, with abundant vascular

240 r type 3 (NTRK3) in both PAND patients and a transgenic mouse model (TgNTRK3) may have a role in PAND

241 We did this using an inducible Zap70 transgenic mouse model that allowed Zap70-dependent sign

242 We developed a transgenic mouse model that allows for lung-specific exp

243 , here we generate an RNA interference-based transgenic mouse model that allows tetracycline-dependen

244 We developed a transgenic mouse model that constitutively expresses a f

245 rance of prion aggregates in the muscle of a transgenic mouse model that develops profound muscle deg

246 Previous studies described a TDP-43(A315T) transgenic mouse model that develops progressive motor d

247 A transgenic mouse model that expresses a constitutively a

248 on in vivo, we generated and characterized a transgenic mouse model that expresses a non-glycosylated

249 We developed a transgenic mouse model that expresses cone PDE6 in rods

250 Here, we have generated a double-transgenic mouse model that expresses human CD1b and CD1

251 Our transgenic mouse model that expresses LacZ reporter unde

252 We created a transgenic mouse model that expresses the pH-dependent f

253 In this study, we generated a transgenic mouse model that expresses TLX under the cont

254 study, we show in a humanized HLA-DRB1*04:02-transgenic mouse model that HLA-DRB1*04:02-restricted T

255 Using a transgenic mouse model that inducibly expresses Dkk1 in

256 newly generated mThy-1 alpha-synuclein E57K transgenic mouse model that is prone to forming oligomer

257 g electrophysiology, cellular markers, and a transgenic mouse model that specifically labels GABA cel

258 Here, we show through a conditional transgenic mouse model that the MYC oncogene, but not th

259 We have generated a transgenic mouse model that ubiquitously expresses a tri

260 Here, we provide evidence from transgenic mouse models that Crebbp deletion results in

261 Here, we used the Vav1 promoter to generate transgenic mouse models that expressed either human STAT

262 and prepubertal development we generated two transgenic mouse models that permit controlled, cell-spe

263 Using transgenic mouse models, these results demonstrate that

264 We generated a transgenic mouse model (TNF-alpha(glo)) that could be us

265 In this issue of the JCI, Pham et al. use a transgenic mouse model to demonstrate that STAT5BN642H i

266 We have used a transgenic mouse model to examine how variations in the

267 gionally restricted and temporally regulated transgenic mouse model to investigate the behavioral, mo

268 We developed a triple-transgenic mouse model to map the fate of NG2(+)CD146(+)

269 ystrophin with utrophin and analyzed several transgenic mouse models to identify phenotypes of the md

270 Despite the extensive use of transgenic mouse models to investigate the propagation o

271 The authors generated a double-transgenic mouse model, tTAxalphaMHCR403Q, in which expr

272 A transgenic mouse model was established to mimic the 10-1

273 ntioxidants in patient cell cultures and the transgenic mouse model, we believe that preventing forma

274 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model, we found that inhibition of RIPK

275 Using our transgenic mouse model, we found that tetherin expressio

276 ne-targeting approach to delete TNFRII in AD transgenic mouse model, we found that, in the brain of A

277 Here, using a tissue-specific miRNA transgenic mouse model, we show that interaction between

278 Using transgenic mouse models, we demonstrate that lymphatic e

279 Using different transgenic mouse models, we demonstrated that muscle-spe

280 Using targeted transgenic mouse models, we found that Vegfa is expresse

281 Using transgenic mouse models, we show that B-cell-specific co

282 METHODS AND To address the question, 2 transgenic mouse models were generated: a phospho-mimeti

283 To address this, we used a transgenic mouse model where Lamin B1 overexpression is

284 Herein, we use a novel transgenic mouse model, where doxycycline-induced overex

285 We turned to the DO11.10 TCR transgenic mouse model, where OVA is recognized in the c

286 yl-D-aspartate receptors are reduced in this transgenic mouse model, which might underlie the observe

287 ectrophysiological recordings in the rTg4510 transgenic mouse model, which overexpresses a mutant for

288 ed sialylation during kidney maturation in a transgenic mouse model, which was restricted to glomerul

289 This further-characterized transgenic mouse model will be useful for advancing MERS

290 ediated skin cancer by interbreeding an HPV8 transgenic mouse model with a conditional disruption of

291 on of a novel herpes-susceptible HLA-A*02:01 transgenic mouse model with ASYMP epitopes, but not with

292 Using a transgenic mouse model with cardiac-specific overexpress

293 of TRAF3IP2 in heart disease, we generated a transgenic mouse model with cardiomyocyte-specific TRAF3

294 ere, we report the generation of a claudin-1 transgenic mouse model with doxycycline-inducible transg

295 s phenomenon, we have developed an inducible transgenic mouse model with expression of the most commo

296 p52 expression in vivo, we generated a novel transgenic mouse model with inducible expression of p52

297 In this study, we use a transgenic mouse model with T cells specific for the mer

298 ional effects of TMPRSS2:ERG expression in a transgenic mouse model with those of ERG knockdown in a

299 er-induced choroidal neovascularization, and transgenic mouse models with deficient or spontaneous re

300 Transgenic mouse models with human monogenic-migraine-sy